Order Article Reprints

Juan A, Noblejas-López MdM, Bravo I, Arenas-Moreira M, Blasco-Navarro C, Clemente-Casares P, Lara-Sánchez A, Pandiella A, Alonso-Moreno C, Ocaña A. Enhanced Antitumoral Activity of Encapsulated BET Inhibitors When Combined with PARP Inhibitors for the Treatment of Triple-Negative Breast and Ovarian Cancers. Cancers. 2022; 14(18):4474. https://doi.org/10.3390/cancers14184474

Juan, Alberto, María del Mar Noblejas-López, Iván Bravo, María Arenas-Moreira, Cristina Blasco-Navarro, Pilar Clemente-Casares, Agustín Lara-Sánchez, Atanasio Pandiella, Carlos Alonso-Moreno, and Alberto Ocaña. 2022. "Enhanced Antitumoral Activity of Encapsulated BET Inhibitors When Combined with PARP Inhibitors for the Treatment of Triple-Negative Breast and Ovarian Cancers" Cancers 14, no. 18: 4474. https://doi.org/10.3390/cancers14184474

Juan, A., Noblejas-López, M. d. M., Bravo, I., Arenas-Moreira, M., Blasco-Navarro, C., Clemente-Casares, P., Lara-Sánchez, A., Pandiella, A., Alonso-Moreno, C., & Ocaña, A. (2022). Enhanced Antitumoral Activity of Encapsulated BET Inhibitors When Combined with PARP Inhibitors for the Treatment of Triple-Negative Breast and Ovarian Cancers. Cancers, 14(18), 4474. https://doi.org/10.3390/cancers14184474